Moleculin Biotech Gets Authorization In The U.K. To Begin Phase 1a Trial Of WP1122

(RTTNews) - Moleculin Biotech, Inc. (MBRX) has received authorization from the Medicines and Healthcare Products Regulatory Agency to commence a phase 1a clinical trial of WP1122 for the treatment of COVID-19 in the United Kingdom. Also, the company has received a favorable opinion from the London - Riverside Research Ethics Committee in the UK to begin the study.

"The potent antiviral effect demonstrated by WP1122 in preclinical models to-date is encouraging and bolsters our belief in its potential as an effective therapy for COVID-19," said Walter Klemp, Chairman and CEO of Moleculin.